Merck Sells Its Federally Financed COVID Pill to US for 40 Times What It Costs to Produce

Fake news media outlets celebrated the announcement last week by Merck Corporation that they had developed a treatment for COVID.

It comes nearly a year since hydroxychloroquine had been discovered to be effective in the treatment of the coronavirus early in its development and just months after Ivermectin was found to have amazing results in the treatment of the coronavirus especially in India.

Merck does not give away their drug. This company charges the US 40 times more to make their drug.

It’s another win for Big Pharma

TRENDINGEXPLUSIVE VIDEO Fauci and HHS officials plot for ‘An Avian Flu Virus to Force Universal Flu Vaccination’ (VIDEO).

According to The Intercept:

A FIVE-DAY COURSE of molnupiravir, the new medicine being hailed as a “huge advance” in the treatment of Covid-19, costs $17.74 to produce, according to a report issued last week by drug pricing experts at the Harvard School of Public Health and King’s College Hospital in London. Merck charges the U.S. $712 for the exact same medicine. This is 40 times more than the cost of the original.

Last Friday’s announcement that the new medicine cut the risk of hospitalization among clinical trial participants with moderate or mild illness in half could have huge implications for the course of the coronavirus pandemic. Because it’s a pill — as opposed to monoclonal antibodies, a comparable antiviral treatment that is administered intravenously — molnupiravir is expected to be more widely used and, hopefully, will cut the death rate. According to Merck and Ridgeback Biotherapeutics (the two companies that jointly launched it), no deaths occurred among 385 people who were given the drug. Eight of those who had received placebos died.

This pill will have huge consequences for your health and may also be a lucrative investment for Ridgeback Biotherapeutics and Merck. Ridgeback, a small Miami company that licensed the medication from Emory University in 2020, sold Merck the worldwide rights two months later for an undisclosed amount. Although Ridgeback remains involved in the development of the drug, some have described the deal as “flipping.”